Radius common stock is traded on the NASDAQ Global Market under the ticker symbol "RDUS."

750469 207

950 Winter St
Waltham, MA 02451

Radius does not offer a direct stock purchase plan. Shares of the Company should be purchased through a broker.

Radius does not currently pay a dividend.

Wells Fargo Shareowner Services
1110 Centre Pointe Curve
Ste. 101
Mendota Heights, MN 55120-4100
(800) 468-9716

To replace lost certificates, contact the transfer agent at:

Wells Fargo Shareowner Services
1110 Centre Pointe Curve
Ste. 101
Mendota Heights, MN 55120-4100
(800) 468-9716

To notify of a change in address, contact the transfer agent at:

Wells Fargo Shareowner Services
1110 Centre Pointe Curve
Ste. 101
Mendota Heights, MN 55120-4100
(800) 468-9716

Radius’ fiscal year is based on the calendar year.

First Quarter ends 3/31, Second Quarter ends 6/30, Third Quarter ends 9/30 and Fourth Quarter ends 12/31.

Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases.

Radius’ lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the treatment of postmenopausal women with osteoporosis. Radius’ Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe and a New Drug Application (NDA) is under regulatory review in the US by the Food and Drug Administration, with a Prescription Drug User Fee Act (PDUFA) date of June 30, 2017. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in postmenopausal women with osteoporosis and the investigational drug RAD1901 for potential use in the treatment of hormone-driven and/or hormone-resistant breast cancer, as well as for potential use in the treatment of vasomotor symptoms in postmenopausal women. Radius’ preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in the treatment of breast cancer.

Please submit your question using the form below.

Contact Form
* Indicates required field
http://apps.shareholder.com/captcha/captcha.aspx?verifyid=1803487611&CompanyID=AMDA-1D3H6P&t=.jpg